EUVIMEDEUVIMED entdecken
Multizentrische Studie

Predictors of remission and relapse in retroperitoneal fibrosis

Milena Bond, Alessandra Bettiol, Eugenia Accorsi Buttini, Giorgio Trivioli, Giulia Palazzini, Ilaria Fibbi, Michelangelo Tesi, Edoardo Biancalana, Christian Dejaco, Giacomo Emmi, Augusto Vaglio

Journal of Internal Medicine · 2025-11 · 298 (5) · 438-449

DOI: 10.1111/joim.70017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Internal Medicine, online erschienen am 26.08.2025. Verfasst von Milena Bond und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy. Hauptthemen laut MEDLINE: Retroperitoneal Fibrosis, Immunosuppressive Agents, Glucocorticoids, Retroperitoneal Space. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In retroperitoneal fibrosis (RPF), glucocorticoids (GC), alone or in combination with immunosuppressive agents, induce remission in 80%–90% of patients but up to two thirds of them relapse. There is limited knowledge on outcome predictors in RPF. We aimed to identify clinical, laboratory and imaging predictors of remission and relapse in RPF.

Methods

We included consecutive RPF patients treated with 6–9‐month courses of GC with/without immunosuppressive agents. Baseline and post‐treatment computed tomography, magnetic resonance imaging and 18 F‐fluorodeoxyglucose ( 18 F‐FDG) positron emission tomography (PET) were assessed. The potential predictive value of the examined parameters as predictors of remission and time‐to‐relapse was analysed using logistic and Cox regression models.

Results

Of 152 patients screened, 115 were included. Of them, 101 (87.8%) achieved remission a median of 4 months (interquartile range 3–5) after starting treatment. At multivariable analysis, smoking (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.11–0.99) and atypical RPF localization (e.g., pelvic) (OR 0.11, 95% CI 0.02–0.52) were negatively associated with remission, whereas pre‐treatment 18 F‐FDG‐PET activity was positively associated (OR 11.51, 95% CI 1.35–98.20). A median of 33 months (17–57) after treatment initiation, 42% patients relapsed (median time from remission to relapse, 14 months [8–26]). Thoracic vessel involvement and positive 18 F‐FDG‐PET at the end of treatment independently predicted relapse (hazard ratio [HR] 2.61, 95% CI 1.19–5.68 and HR 3.47, 95% CI 1.54–7.82, respectively).

Conclusions

Metabolic activity of RPF at 18 F‐FDG‐PET is an important predictor of remission and relapse. Smoking and atypical localization are negatively associated with remission, whereas thoracic aorta involvement is associated with relapse risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retroperitoneal FibrosisImmunosuppressive AgentsGlucocorticoidsRetroperitoneal SpacePositron-Emission TomographyDrug Therapy, CombinationRemission InductionRecurrenceTreatment OutcomeFluorodeoxyglucose F18SmokingRisk FactorsTomography, X-Ray ComputedMagnetic Resonance ImagingRetrospective StudiesFollow-Up StudiesHumansMaleFemaleMiddle Aged

Stichwörter der Autor:innen

IgG4periaortitispositron emission tomography (PET)retroperitoneal fibrosisvasculitis

Substanzen

Immunosuppressive AgentsGlucocorticoidsFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy.
  • Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy.
  • Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Haematology Research Program, Department of Clinical and Experimental Science, ASST Spedali Civili di Brescia, University of Brescia, Brescia, I…
  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Zitieren

APA

Bond, M., Bettiol, A., Buttini, E. A., Trivioli, G., Palazzini, G., Fibbi, I., Tesi, M., Biancalana, E., Dejaco, C., Emmi, G., & Vaglio, A. (2025). Predictors of remission and relapse in retroperitoneal fibrosis. Journal of Internal Medicine, 298(5), 438-449. https://doi.org/10.1111/joim.70017

Vancouver

Bond M, Bettiol A, Buttini EA, Trivioli G, Palazzini G, Fibbi I, et al. Predictors of remission and relapse in retroperitoneal fibrosis. Journal of Internal Medicine. 2025;298(5):438-449. doi:10.1111/joim.70017

BibTeX
@article{Bond2025,
  author = {Bond, Milena and Bettiol, Alessandra and Buttini, Eugenia Accorsi and Trivioli, Giorgio and Palazzini, Giulia and Fibbi, Ilaria and Tesi, Michelangelo and Biancalana, Edoardo and Dejaco, Christian and Emmi, Giacomo and Vaglio, Augusto},
  title = {Predictors of remission and relapse in retroperitoneal fibrosis},
  journal = {Journal of Internal Medicine},
  year = {2025},
  volume = {298},
  number = {5},
  pages = {438--449},
  doi = {10.1111/joim.70017}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche